ADVFN Post26 Jun 2025 16:23
I've been looking over on the above and saw this.
Any views on what the poster has commented?
Talk of people going the AGM may want to ask these questions
A few thoughts on the accounts:
1.What are the terms of the 2022 agreement under which Infusion [Illusion?] Ltd provides the services of FG to QBT?The accounts and statement do not suggest that there was any obligation to pay the 'performance' bonus [Ā£100k], or an increased basic fee.
2. How independent of FG are the directors of QBT who negotiated [volunteered?]this 33% uplift in fees?
3. If Infusion [FG] is in a contractual position to achieve a 33% hike in fees on the basis of the achievements in 2024 ( the year in which expected [by FG !!] revenue failed to materialise), what would QBT be constrained to pay in the event that the tech is commercialised?
Hint: there are only 2 alternatives. Either there was no contractual obligation to give the uplift and it was just a a 'gift' from a BoD dancing to FG's tune, or there was a contractual obligation. If 2024's results entitled Fg to that performance payment and hike iun basic fees, what would commercialisation and revenue entitle him to? And if a compliant BoD was prepared to make a non-contractual 'gift' of that order to Fg on the basis of the 2024 results, what would be the magnitude of the gift in the event odf commercialisation and revenue?
To my mind it is too generous to describe QBT merely as a hobby company. It is structured to provide a huge income to FG while it continues to make losses, and a vehicle for transferring the fruits of any success to FG. FG takes an income of staggering size in relation to turnover, capitalisation, size of workforce, his own hours, and accruing losses (do your own comparisons with other small companies). while standing to scoop the pool in the event of commercial success, without taking any personal financial risk.
Whose benefit is QBT being operated for? the CEO's or the shareholders'?
3. What special litigation expertise does FG provide to warrant his 10% cut of any Sipiem recoveries? It is pretty unusual for a CEO to have deal like that. As I see it QBT pays 100% of the cost of the litigation, so for FG it is a 'heads I win, tails I don't lose' situation, so he has an incentive to keep poring QBT's money into the litigation, however small the prospects of ultimate success. [Note: the Court of Appeal judgment was not final. It is under appeal with a decision 'several years ' off. Enforcement is not barred in the meantime, but any money recovered would have to be repaid with interest (and possibly an inflation uplift) if QBT loses the appeal]
4.Anyone thinking about investing in QBT should pay careful attention to the capital structure outlined in the accounts, particularly the bond terms. In the event that QBT 's tech does come good and the bonds are converted to equity, calculate the dilutive effect on the holders of ordinary shares.
Those who calculate shareholder risk /